ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2025
Medication adherence and real-world factors of first line induction treatment selection in ANCA-associated vasculitis.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
objectiveThis study aimed to explore real-world factors that may influence the selection of first-line remission-induction therapy in ANCA-associated vasculitis(AAV), as well as to evaluate physician compliance with guideline recommendations and patient adherence to maintenance therapies.
methodsA retrospective analysis of 112 patients with AAV, including granulomatosis with polyangiitis(GPA, 67%), microscopic polyangiitis(MPA, 13%),and eosinophilic granulomatosis with polyangiitis (EGPA, 20%), was conducted at a single tertiary care center using electronic health records from 2018 to 2023. Treatment regimens, patient demographics, organ involvement, and adherence to EULAR guidelines were analyzed.Patients receiving RTX or CYC as first-line remission-induction therapy were compared.Compliance was defined as alignment with guideline-recommended dosing and timing of induction therapy, while adherence during maintenance was evaluated based on consistency with prescribed regimens, assessed via prescription refill data.
resultsOf the 102 patients included in the study, 85 received CYC and 17 received RTX as first-line remission induction therapy.Compared to the RTX group, those receiving CYC were significantly older (median age 57 vs. 44 years, p <0.05), had higher BVAS scores (median 12 vs. 10, p = 0.02), and exhibited more comorbidities (74% vs. 35%). Organ involvement rates were similar in both groups. No significant differences in major organ involvement were observed between the two groups. RTX adherence was 100% in both the induction and maintenance phases, whereas adherence to oral maintenance therapies was notably lower, at 66% for methotrexate, 36% for mycophenolate mofetil, and 28% for azathioprine.
conclusionIn real-world practice, older age, higher BVAS, and a greater comorbidity burden appear to influence clinicians' preference for CYC over RTX as first-line induction,despite similar organ involvement between groups.Overall compliance with induction guidelines was high,but adherence to oral maintenance regimens remained suboptimal.These findings underscore the need for personalized treatment strategies and targeted measures to enhance long-term medication adherence in AAV.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.